Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mizuki Nishino Hatabu, M.D.

Co-Author

This page shows the publications co-authored by Mizuki Nishino Hatabu and Frank Hodi.
Connection Strength

9.268
  1. Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. Radiology. 2019 01; 290(1):9-22.
    View in: PubMed
    Score: 0.789
  2. Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. Cancer Immunol Res. 2018 06; 6(6):630-635.
    View in: PubMed
    Score: 0.755
  3. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017 Nov; 14(11):655-668.
    View in: PubMed
    Score: 0.716
  4. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res. 2017 Aug 15; 23(16):4671-4679.
    View in: PubMed
    Score: 0.713
  5. Risk of Bias and Heterogeneity-Reply. JAMA Oncol. 2017 06 01; 3(6):858-859.
    View in: PubMed
    Score: 0.712
  6. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Dec 01; 2(12):1607-1616.
    View in: PubMed
    Score: 0.688
  7. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016 Dec 15; 22(24):6051-6060.
    View in: PubMed
    Score: 0.674
  8. Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015 Jul; 84(7):1259-68.
    View in: PubMed
    Score: 0.612
  9. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014; 2(1):40.
    View in: PubMed
    Score: 0.597
  10. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014; 2:17.
    View in: PubMed
    Score: 0.580
  11. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14):3936-43.
    View in: PubMed
    Score: 0.540
  12. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019 04 24; 7(1):112.
    View in: PubMed
    Score: 0.203
  13. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858.
    View in: PubMed
    Score: 0.186
  14. Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 Oct 01; 23(19):5737-5744.
    View in: PubMed
    Score: 0.179
  15. Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.178
  16. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean J Radiol. 2017 Jan-Feb; 18(1):42-53.
    View in: PubMed
    Score: 0.173
  17. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016; 4:84.
    View in: PubMed
    Score: 0.173
  18. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. Br J Haematol. 2018 03; 180(5):752-755.
    View in: PubMed
    Score: 0.171
  19. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2016 Apr; 4(4):289-93.
    View in: PubMed
    Score: 0.163
  20. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015 Jul 16; 373(3):288-90.
    View in: PubMed
    Score: 0.156
  21. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Oct; 3(10):1185-92.
    View in: PubMed
    Score: 0.156
  22. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res. 2015 Sep; 3(9):986-91.
    View in: PubMed
    Score: 0.154
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.